Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
United Therapeutics Corporation disclosed that new director Kevin Tracey received a grant of restricted stock units on January 21, 2026. The award covers 1,220 restricted stock units, each representing the right to receive one share of United Therapeutics common stock after vesting. The units were granted at a price of $0.00 in connection with his appointment to the Board of Directors under the company’s Non-Employee Director Compensation Program.
The award becomes fully vested on the one-year anniversary of the grant date, January 21, 2027. Following this grant, Tracey beneficially owns 1,220 derivative securities in the form of restricted stock units, held directly.
United Therapeutics Corp director Tracey Kevin filed an initial ownership report on Form 3. The filing states that no United Therapeutics securities are beneficially owned. This means the reporting person, who is a director of the company, is formally disclosing that they do not currently hold any direct or indirect ownership in the company’s stock or derivative securities under the applicable reporting rules.
United Therapeutics Corporation reported governance updates. On January 21, 2026, the Board of Directors increased its size to 13 members and appointed Kevin J. Tracey, M.D. as a new director, based on the recommendation of the Nominating and Governance Committee. He will initially serve without a committee assignment, and the company states there are no related-party transactions involving him above the disclosure threshold.
In connection with his appointment, Dr. Tracey received 1,220 restricted stock units under the company’s Amended and Restated 2015 Stock Incentive Plan, consistent with its standard non-employee director compensation program, and entered into the company’s standard indemnification agreement for directors and executive officers. The Board also approved and put into effect the Eleventh Amended and Restated Bylaws, which restate and amend the prior bylaws and include various technical conforming changes. A press release announcing Dr. Tracey’s appointment was furnished as an exhibit.
United Therapeutics director Malcolm Jan reported a small planned stock sale. On January 16, 2026, he sold 50 shares of United Therapeutics common stock at $460.98 per share in an open market transaction coded as a sale. The filing notes that this trade was executed under a pre-established Rule 10b5-1 trading plan that the reporting person entered into on September 11, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, he beneficially owned 320 shares of the company’s common stock in direct ownership.
A shareholder of UTHR, identified as Jan Malcolm, has filed a Form 144 notice to sell 50 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with the shares listed on NASDAQ. The shares to be sold were acquired as restricted stock from the issuer on 06/26/2025, and the planned sale has an indicated aggregate market value of $23,049.00. The notice states that there were 43,056,599 shares of the same class outstanding. Over the prior three months, Jan Malcolm sold an additional 150 common shares in three transactions, with gross proceeds of $25,606.00, $24,149.00, and $24,750.50, respectively.
United Therapeutics Corp EVP & General Counsel Paul A. Mahon reported an option exercise and related share sales in company stock. On January 15, 2026, he exercised a stock option for 8,300 shares of common stock at an exercise price of $146.03 per share. The exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan that he entered into on August 11, 2025.
On the same day, he reported multiple open-market sales of common stock in several blocks, including transactions of 1,439 shares at $468.324, 1,307 shares at $470.3663, 407 shares at $472.2826, 3,531 shares at $469.3392, 1,576 shares at $471.4401, and 40 shares at $474.74. After these transactions, Mahon directly held 36,781 shares of United Therapeutics common stock and 58,400 stock options remained beneficially owned following the reported option exercise.
An affiliate of UTHR has filed a Form 144 to sell 8,300 common shares, with an aggregate market value of $3,900,121.86. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/15/2026. The shares were acquired on the same date via a stock option exercise paid in cash.
The notice also lists prior sales by Paul Mahon over the past three months, including several transactions of 11,000 common shares each between October and December 2025 and an additional 8,300-share sale on 01/02/2026, with individual gross proceeds in the several-million-dollar range. The filer represents that they are not aware of undisclosed material adverse information about the issuer.
United Therapeutics Corporation President and COO Michael Benkowitz reported option exercises and related share sales in United Therapeutics (UTHR) on January 12, 2026.
Trusts associated with him exercised 14,625 stock options at $117.76 per share and 7,875 stock options at $146.03 per share, then sold the same numbers of common shares at $479.5056 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on June 3, 2025.
After these trades, one trust held 82,500 stock options and another held 44,440 stock options, and Benkowitz also held 2,648 shares of common stock directly. The filing notes that one trust is co‑managed by him and his spouse, while another is managed solely by him for the benefit of family members.
United Therapeutics president and COO Michael Benkowitz reported an option exercise and related share sales made through a trust. On January 5, 2026, a trust for his benefit exercised 14,625 stock options at an exercise price of
The filing states that this option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on June 3, 2025. Following these transactions, a trust associated with Benkowitz continues to hold 97,125 stock options, and he also reports 2,648 shares of common stock held directly.
United Therapeutics Corp’s president and COO Michael Benkowitz, through a family trust, reported an option exercise and related share sales. On January 5, 2026, the trust exercised 7,875 stock options at an exercise price of $146.03 per share, receiving the same number of common shares. Those 7,875 shares of common stock were then sold in multiple open‑market transactions at weighted‑average prices ranging from about $480.32 to $494.41, all reported as indirect ownership "by Trust."
The filing states that the exercise and sales were made under a Rule 10b5‑1 trading plan entered into on June 3, 2025. After these sales, the trust no longer holds common stock, while Benkowitz is shown as directly owning 2,648 shares of common stock and indirectly holding 52,315 stock options through the trust.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
